Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Replimune Group Inc
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune to Present at the 2025 Jefferies Global Healthcare Conference
May 29, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
May 22, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day
May 16, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 09, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
February 12, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
January 21, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
January 08, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Pricing of Upsized Public Offering
November 25, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Proposed Public Offering
November 25, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
November 21, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
November 09, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 08, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 30, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.